Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales

  • Rochelle Knight
    Department of Population Health Sciences, Bristol Medical School, University of Bristol, UK (R.K., V.W., J.A.C., R.D., T.-L.N., R.T., G.D.S., J.A.C.S.).
  • Venexia Walker
    Department of Population Health Sciences, Bristol Medical School, University of Bristol, UK (R.K., V.W., J.A.C., R.D., T.-L.N., R.T., G.D.S., J.A.C.S.).
  • Samantha Ip
    British Heart Foundation Cardiovascular Epidemiology Unit (S.I., T.B., S.K., X.J., E.D.A., A.M.W.), University of Cambridge, UK.
  • Jennifer A. Cooper
    Department of Population Health Sciences, Bristol Medical School, University of Bristol, UK (R.K., V.W., J.A.C., R.D., T.-L.N., R.T., G.D.S., J.A.C.S.).
  • Thomas Bolton
    British Heart Foundation Cardiovascular Epidemiology Unit (S.I., T.B., S.K., X.J., E.D.A., A.M.W.), University of Cambridge, UK.
  • Spencer Keene
    British Heart Foundation Cardiovascular Epidemiology Unit (S.I., T.B., S.K., X.J., E.D.A., A.M.W.), University of Cambridge, UK.
  • Rachel Denholm
    Department of Population Health Sciences, Bristol Medical School, University of Bristol, UK (R.K., V.W., J.A.C., R.D., T.-L.N., R.T., G.D.S., J.A.C.S.).
  • Ashley Akbari
    Population Data Science, Swansea University Medical School, Swansea University, Wales, UK (A.A., H.A., F.T.).
  • Hoda Abbasizanjani
    Population Data Science, Swansea University Medical School, Swansea University, Wales, UK (A.A., H.A., F.T.).
  • Fatemeh Torabi
    Population Data Science, Swansea University Medical School, Swansea University, Wales, UK (A.A., H.A., F.T.).
  • Efosa Omigie
    National Health Service Digital, Leeds, UK (E.O., S.H.).
  • Sam Hollings
    National Health Service Digital, Leeds, UK (E.O., S.H.).
  • Teri-Louise North
    Department of Population Health Sciences, Bristol Medical School, University of Bristol, UK (R.K., V.W., J.A.C., R.D., T.-L.N., R.T., G.D.S., J.A.C.S.).
  • Renin Toms
    Department of Population Health Sciences, Bristol Medical School, University of Bristol, UK (R.K., V.W., J.A.C., R.D., T.-L.N., R.T., G.D.S., J.A.C.S.).
  • Xiyun Jiang
    British Heart Foundation Cardiovascular Epidemiology Unit (S.I., T.B., S.K., X.J., E.D.A., A.M.W.), University of Cambridge, UK.
  • Emanuele Di Angelantonio
    British Heart Foundation Cardiovascular Epidemiology Unit (S.I., T.B., S.K., X.J., E.D.A., A.M.W.), University of Cambridge, UK.
  • Spiros Denaxas
    Health Data Research UK (S.D.), London.
  • Johan H. Thygesen
    Institute of Health Informatics (S.D., J.H.T., C.T.), University College London, UK.
  • Christopher Tomlinson
    Institute of Health Informatics (S.D., J.H.T., C.T.), University College London, UK.
  • Ben Bray
    School of Population Health and Environmental Sciences, King’s College London, UK (B.B.).
  • Craig J. Smith
    Geoffrey Jefferson Brain Research Centre, Manchester Centre for Clinical Neurosciences, Northern Care Alliance National Health Service Foundation Trust, Salford Royal Hospital, UK (C.J.S.).
  • Mark Barber
    Glasgow Caledonian University, UK (M.B.).
  • Kamlesh Khunti
    Diabetes Research Centre, University of Leicester, UK (K.K.).
  • George Davey Smith
    Department of Population Health Sciences, Bristol Medical School, University of Bristol, UK (R.K., V.W., J.A.C., R.D., T.-L.N., R.T., G.D.S., J.A.C.S.).
  • Nishi Chaturvedi
    MRC Unit for Lifelong Health and Ageing at UCL, Institute of Cardiovascular Science (N.C.), University College London, UK.
  • Cathie Sudlow
    British Heart Foundation Data Science Centre (T.B., C.S.), London.
  • William N. Whiteley
    Centre for Clinical Brain Sciences, University of Edinburgh, UK (W.N.W.).
  • Angela M. Wood
    British Heart Foundation Cardiovascular Epidemiology Unit (S.I., T.B., S.K., X.J., E.D.A., A.M.W.), University of Cambridge, UK.
  • Jonathan A.C. Sterne
    Department of Population Health Sciences, Bristol Medical School, University of Bristol, UK (R.K., V.W., J.A.C., R.D., T.-L.N., R.T., G.D.S., J.A.C.S.).

抄録

<jats:sec> <jats:title>Background:</jats:title> <jats:p>Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a prothrombotic state, but long-term effects of COVID-19 on incidence of vascular diseases are unclear.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>We studied vascular diseases after COVID-19 diagnosis in population-wide anonymized linked English and Welsh electronic health records from January 1 to December 7, 2020. We estimated adjusted hazard ratios comparing the incidence of arterial thromboses and venous thromboembolic events (VTEs) after diagnosis of COVID-19 with the incidence in people without a COVID-19 diagnosis. We conducted subgroup analyses by COVID-19 severity, demographic characteristics, and previous history.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Among 48 million adults, 125 985 were hospitalized and 1 319 789 were not hospitalized within 28 days of COVID-19 diagnosis. In England, there were 260 279 first arterial thromboses and 59 421 first VTEs during 41.6 million person-years of follow-up. Adjusted hazard ratios for first arterial thrombosis after COVID-19 diagnosis compared with no COVID-19 diagnosis declined from 21.7 (95% CI, 21.0–22.4) in week 1 after COVID-19 diagnosis to 1.34 (95% CI, 1.21–1.48) during weeks 27 to 49. Adjusted hazard ratios for first VTE after COVID-19 diagnosis declined from 33.2 (95% CI, 31.3–35.2) in week 1 to 1.80 (95% CI, 1.50–2.17) during weeks 27 to 49. Adjusted hazard ratios were higher, for longer after diagnosis, after hospitalized versus nonhospitalized COVID-19, among Black or Asian versus White people, and among people without versus with a previous event. The estimated whole-population increases in risk of arterial thromboses and VTEs 49 weeks after COVID-19 diagnosis were 0.5% and 0.25%, respectively, corresponding to 7200 and 3500 additional events, respectively, after 1.4 million COVID-19 diagnoses.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>High relative incidence of vascular events soon after COVID-19 diagnosis declines more rapidly for arterial thromboses than VTEs. However, incidence remains elevated up to 49 weeks after COVID-19 diagnosis. These results support policies to prevent severe COVID-19 by means of COVID-19 vaccines, early review after discharge, risk factor control, and use of secondary preventive agents in high-risk patients.</jats:p> </jats:sec>

収録刊行物

  • Circulation

    Circulation 146 (12), 892-906, 2022-09-20

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ